An AllTrials project

NCT03049189: An ongoing trial by ITM Solucin GmbH

This trial is ongoing. It must report results 10 months, 3 weeks from now.

Full data

Full entry on ClinicalTrials.gov NCT03049189
Title A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Feb. 2, 2017
Completion date Dec. 31, 2024
Required reporting date Dec. 31, 2025, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov Feb. 9, 2024
Days late None